DEXCOM, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 125 USD | -1.65% |
|
-3.63% | +0.69% |
| 04-30 | Glutality Powered by StrideMD Announces Integration with Dexcom to Enhance Remote Diabetes Care with CGM Technology | CI |
| 04-26 | Wall Street: the worst week of 2024 is followed by the best | CF |
Presentation Operator MessageOperator (Operator)Welcome to the DexCom Second Quarter 2021 Earn...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
DexCom, Inc. specializes in the design, manufacture and marketing of continuous glucose monitoring (CGM) systems for people with diabetes and healthcare providers. The company provides an implantable device for continuous measurement of blood glucose levels and an external transmitter to which the sensor transmits glucose levels at specified intervals.
The United States accounts for 72.5% of net sales.
Calendar
2024-05-21
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
125
USD
Average target price
150.9
USD
Spread / Average Target
+20.74%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +0.69% | 49.69B | |
| -4.82% | 182B | |
| +1.38% | 111B | |
| -2.82% | 68.48B | |
| +8.54% | 44.46B | |
| +2.33% | 40.67B | |
| +20.50% | 31.22B | |
| +1.72% | 26.09B | |
| +15.30% | 25.32B | |
| -1.73% | 24.6B |
- Stock Market
- Equities
- DXCM Stock
- News DexCom, Inc.
- Transcript : DexCom, Inc., Q2 2021 Earnings Call, Jul 29, 2021